NICE implementation uptake & commissioned reports

The NICE Implementation Directorate will produce in-house implementation uptake reports to assess the level of compliance with guidance across the NHS. NICE has also previously commissioned a number of external reports and surveys on the uptake of guidance.

The NICE implementation uptake reports will be based on the analysis of data that is available at a national level from a number of sources including:

• ePACT: the Prescribing Analysis and Cost Tool system which covers prescriptions prescribed in primary care in England
• FP10(HP): information covering prescriptions written in hospitals intended for dispensing in the community
• IMS HPAI: the IMS Health Hospital Pharmacy Audit Index (IMS HPAI) database which covers issues of medicines recorded on hospital pharmacy systems in the UK.
• HES: the Hospital Episodes Statistics national datawarehouse provides a range of information on the care provided by NHS hospitals in England and for NHS hospital patients treated elsewhere

Details of the methods used will be included in each implementation uptake report. Each report will aim to examine trends in the use of a drug, procedure or technology recommended in NICE guidance. In some cases additional analysis will be presented that estimates the uptake in line with assumptions based on the NICE recommendations.

The extent of the in-house reports may be limited by the data available. These limitations will vary depending on the information available and the guidance under consideration. The limitations and data sources will be detailed in each report.

The following uptake reports are available:

• Management of rheumatoid arthritis in adults
• Anxiety (amended)
• Heavy menstrual bleeding
• Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease
• Omalizumab for severe persistent allergic asthma
• Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolemia
• Pimecrolimus and tacrolimus for atopic eczema
• Drugs used to treat hepatitis C
• Diabetes (types 1 and 2) - insulin glargine
• Diabetes - glitazones (rosiglitazone and pioglitazone)
• Epilepsy - the diagnosis and management of the epilepsies in adults and children in primary and secondary care
• Obesity - surgical interventions
• Myocardial infarction (MI) - secondary prevention
• Pharmacological interventions for obesity
• Newer hypnotic drugs for insomnia
• Statins for the prevention of cardiovascular events
• Capecitabine and oxaliplatin in the adjuvant treatment of stage III colon cancer
• Nicotine replacement therapy (NRT), bupropion and varenicline for smoking cessation
• Adefovir dipivoxil to treat hepatitis B
• Atypical antipsychotics
• Drugs used in the management of urinary incontinence
• Laparoscopic surgery for colorectal cancer
• Laparoscopic surgery for inguinal hernia repair
• Bipolar disorder
• Drotrecogin alfa (activated) for severe sepsis
• Long acting reversible contraception
• Drugs used in the management of hypertension in primary care in England
• Attention deficit hyperactivity disorder (ADHD), management of ADHD in children, young people and adults
• Cox II selective inhibitors
• Riluzole
• NICE commissioned surveys and reports